Sensei

Sensei Biotherapeutics Reports Full Year 2023 Financial Results and Recent Business Highlights

Retrieved on: 
Wednesday, February 28, 2024

BOSTON, Feb. 28, 2024 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), a clinical stage immuno-oncology company focused on the discovery and development of next-generation therapeutics for cancer patients, today reported financial results for the full year 2023, and provided corporate updates.

Key Points: 
  • “2023 saw the entry of our differentiated anti-VISTA antibody, SNS-101, into clinical development,” said John Celebi, President and Chief Executive Officer.
  • Recent updates include:
    A total of 33 patients have been treated with SNS-101 +/- Libtayo in the dose escalation phase of this study.
  • On October 23, 2023 , Sensei presented a trial-in-progress poster from the Phase 1/2 clinical trial for SNS-101 at the European Society for Medical Oncology Congress (ESMO) 2023.
  • On November 1, 2023, Sensei announced the appointment of Stephanie Krebs, MS, MBA, as Chief Business Officer.

Neurala to Collaborate with Lattice Semiconductor to Accelerate Edge AI

Retrieved on: 
Wednesday, February 28, 2024

Today Neurala , a leading provider of vision AI software, announced a new version of Neurala VIA that enables the rapid deployment of AI models based on the award-winning Lattice sensAI™ solution stack and low power Lattice FPGAs.

Key Points: 
  • Today Neurala , a leading provider of vision AI software, announced a new version of Neurala VIA that enables the rapid deployment of AI models based on the award-winning Lattice sensAI™ solution stack and low power Lattice FPGAs.
  • The latest Neurala VIA offers more flexibility, provides advanced edge AI capabilities, and maximizes available compute power, enabling developers to efficiently create and deploy AI models at the edge.
  • Neurala CEO and Co-Founder, Dr. Max Versace said, “Running AI at the edge is increasingly important to reduce power, latency, minimize bandwidth, and increase data privacy.
  • “This collaboration with Neurala is a great example of how Lattice’s low power FPGA technology and sensAI solution stack can help accelerate development cycles and enable designers to build and deploy scalable Edge AI applications.”
    The collaboration between Neurala and Lattice marks a significant milestone in advancing edge AI capabilities.

Spring Break and Easter at Four Seasons: New Experiences and Hotel Features Highlight Last Minute Ideas for Travellers of All Ages

Retrieved on: 
Thursday, February 29, 2024

TORONTO, Feb. 29, 2024 /PRNewswire/ -- Still haven't locked in plans for a family vacation this spring? With spring break and Easter holidays coinciding this year, Four Seasons is ready to welcome travellers with myriad activities and diversions for all ages, showcasing new offerings and renovated rooms, pools and kids clubs along the way.

Key Points: 
  • With spring break and Easter holidays coinciding this year, Four Seasons is ready to welcome travellers with myriad activities and diversions for all ages, showcasing new offerings and renovated rooms, pools and kids clubs along the way.
  • Nearby, the Hotel can arrange horseback riding in the mountains, or surfing in Malibu.
  • Spring break ideas include a surf club for all ages and abilities, jungle zipline adventures, cultural connections in the community, and much more.
  • On Paradise Island, the legendary Ocean Club, A Four Seasons Resort welcomes families for spring break and Easter with Bahamian Straw Markets and Junkaroo entertainment plus a very special Easter Brunch.

SGS Maine Pointe Announces Strategic Alliance with Sensei Labs®

Retrieved on: 
Tuesday, February 20, 2024

PLYMOUTH, Mass., Feb. 20, 2024 /PRNewswire-PRWeb/ -- Global supply chain and operations implementation consulting firm, SGS Maine Pointe, a member of the SGS Group, announced a strategic alliance with Sensei Labs®, to bring Sensei Labs' groundbreaking Conductor® enterprise orchestration platform into the realm of supply chain consulting. Conductor brings a holistic and powerful combination of project and portfolio management, collaboration, data and KPI tracking and reporting, and knowledge management.

Key Points: 
  • PLYMOUTH, Mass., Feb. 20, 2024 /PRNewswire-PRWeb/ -- Global supply chain and operations implementation consulting firm, SGS Maine Pointe , a member of the SGS Group , announced a strategic alliance with Sensei Labs® , to bring Sensei Labs' groundbreaking Conductor® enterprise orchestration platform into the realm of supply chain consulting.
  • Our partnership with Sensei Labs, and the integration of the Conductor platform into our supply chain practice, will enhance our mission and deliver exceptional value to our clients
    The relationship between SGS Maine Pointe and Sensei Labs, and the integration of the Conductor platform, will enable our clients to orchestrate supply chain success.
  • "The fusion of our technological expertise with the renowned supply chain management acumen of SGS Maine Pointe creates a powerful combination," commented Jay Goldman Co-founder and CEO of Sensei Labs.
  • Clients of SGS Maine Pointe will benefit from a more integrated, technology-driven approach to supply chain transformation, positioning them to capture new value and stay ahead in a competitive global market.

Sensei Biotherapeutics to Present at Upcoming Conferences

Retrieved on: 
Wednesday, February 7, 2024

BOSTON, Feb. 07, 2024 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), a clinical stage immuno-oncology company focused on the discovery and development of next generation therapeutics for cancer patients, today announced that Company management will present at the following conferences in February 2024:

Key Points: 
  • BOSTON, Feb. 07, 2024 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), a clinical stage immuno-oncology company focused on the discovery and development of next generation therapeutics for cancer patients, today announced that Company management will present at the following conferences in February 2024:
    A webcast of Sensei’s presentation at Oppenheimer will be available in the Investors section of the Sensei website.
  • A replay of the webcast will be on the website for approximately 90 days following the event.
  • Registration for the webcast is available here.

Sensei Biotherapeutics Provides Corporate Update and Highlights Key Upcoming Milestones

Retrieved on: 
Thursday, January 4, 2024

BOSTON, Jan. 04, 2024 (GLOBE NEWSWIRE) --  Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), a clinical stage immuno-oncology company focused on the discovery and development of next-generation therapeutics for cancer patients, today provided corporate updates on its research and development programs and upcoming milestones.

Key Points: 
  • BOSTON, Jan. 04, 2024 (GLOBE NEWSWIRE) --  Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), a clinical stage immuno-oncology company focused on the discovery and development of next-generation therapeutics for cancer patients, today provided corporate updates on its research and development programs and upcoming milestones.
  • In the monotherapy dose escalation arm, patients have cleared all planned dosing cohorts of 0.3, 1, 3, 10 and 15 mg/kg.
  • Anticipated milestones for the SNS-101 Phase 1/2 clinical trial include:
    Sensei announces that Ron Weitzman, M.D., F.A.C.P., has joined Sensei as part-time Chief Medical Officer.
  • As a result, Sensei will pause IND-enabling work on its preclinical-stage TMAb programs, including SNS-102 (VSIG4), SNS-103 (CD39) and SNS-201 (VISTAxCD28).

New Cloud Imaging Solution Turns Carestream Dental Imaging Systems into Connected Devices

Retrieved on: 
Friday, November 24, 2023

Atlanta, Nov. 24, 2023 (GLOBE NEWSWIRE) -- Dental practices can now synchronize imaging across their entire business by automatically storing CBCT scans and 2D X-rays securely in the cloud with Swissmeda Cloud Imaging.

Key Points: 
  • Atlanta, Nov. 24, 2023 (GLOBE NEWSWIRE) -- Dental practices can now synchronize imaging across their entire business by automatically storing CBCT scans and 2D X-rays securely in the cloud with Swissmeda Cloud Imaging.
  • So, doctors can turn their existing Carestream Dental systems—like the CS 9600 or CS 8200 3D—into cloud-connected devices.
  • “By offering cloud imaging, the Carestream Dental and Swissmeda brands are giving practices easier access to vital clinical information,” Philippe Maillet, general manager, global equipment, Carestream Dental, said.
  • When it’s time to view a stored image, the Swissmeda Cloud Imaging Viewer can be conveniently accessed online.

Toyota Research Institute Showcases Latest AI-Assisted Driving Technology

Retrieved on: 
Wednesday, November 15, 2023

WILLOWS, Calif., Nov. 15, 2023 /PRNewswire/ -- Last month, Toyota Research Institute (TRI) invited reporters for a deep dive into its new Accelerated Concepts program in active safety.

Key Points: 
  • WILLOWS, Calif., Nov. 15, 2023 /PRNewswire/ -- Last month, Toyota Research Institute (TRI) invited reporters for a deep dive into its new Accelerated Concepts program in active safety.
  • TRI's Human Interactive Driving (HID) team aims their research not at self-driving robotaxis but rather at active safety, incorporating both high autonomy AND high driver engagement.
  • Driving Sensei helps people become better, safer drivers while ensuring they are engaged in the driving task.
  • Participants had time behind the wheel to test TRI's custom-built Global Research Innovation Platform (GRIP), a research vehicle with four-wheel steering and in-wheel electric motors used to iterate driving research rapidly.

Dental Revenue Announces software partner program and reseller agreement with Carestream Dental's practice management brand, Sensei

Retrieved on: 
Wednesday, November 8, 2023

BALTIMORE, Nov. 8, 2023 /PRNewswire-PRWeb/ -- A Brief History of Dental Revenue

Key Points: 
  • Dental Revenue, a leader in dental marketing solutions, is excited to announce a Software Partner Program and Reseller Agreement with Sensei, the practice management solution portfolio of Carestream Dental
    "Thanks to API access to all Sensei's practice management solutions, we are jointly offering the most cutting-edge digital marketing and performance measurement tool available today says," Dental Revenue CEO and Founder Brian Burns.
  • Recognizing the unique needs and challenges faced by dental professionals, Dental Revenue was formed in 2015 and launched its highly regarded Performance Program.
  • "Our Performance Program is purpose-built to help dental practices and dental service organizations achieve their business goals," says Dental Revenue CEO and Founder Brian Burns.
  • Sensei includes an expansive portfolio—including Sensei Cloud, OrthoTrac PracticeWorks, SoftDent and WinOMS—that delivers scalable, best-in-class dental practice and patient management solutions.

Sensei Biotherapeutics Reports Third Quarter 2023 Financial Results and Recent Business Highlights

Retrieved on: 
Tuesday, November 7, 2023

BOSTON, Nov. 07, 2023 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), a clinical stage immuno-oncology company focused on the discovery and development of next-generation therapeutics for cancer patients, today reported financial results for the third quarter ended September 30, 2023, and provided recent business updates.

Key Points: 
  • On October 23, 2023, Sensei presented a trial-in-progress poster from the Phase 1/2 clinical trial for SNS-101 at the European Society for Medical Oncology Congress (ESMO) 2023.
  • On November 1, 2023, Sensei announced the announced the appointment of Stephanie Krebs, MS, MBA, as Chief Business Officer.
  • General and Administrative (G&A) Expenses: G&A expenses were $3.9 million for the quarter ended September 30, 2023, compared to $4.8 million for the quarter ended September 30, 2022.
  • Net Loss: Net loss was $7.1 million for the quarter ended September 30, 2023, compared to $13.4 million for the quarter ended September 30, 2022.